Breath test for early lung cancer signs in high-risk adults
Tests breath condensate markers against low-dose CT scans for lung cancer screening.
Plain-language title generated from the registry record
Registry title: Study of Early Cancer Biomarkers in Breath Condensate in Population of Individuals With High-Risk of Lung Cancer Undergoing LDCT Screening.
Key facts
- Where
- Brno, Olomouc, and Prague, CzechiaSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 74 years old?
Source: NCT06016569, who can take part
Where in Czechia
- Masaryk Memorial Cancer InstituteBrno, CzechiaTaking people
- University HospitalOlomouc, CzechiaNot yet recruiting
- General University Hospital in PraguePrague, CzechiaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Institute of Molecular and Translational Medicine, Czech Republic
- Trial code
- NCT06016569
- Record updated
- 12 February 2026
- Original description
The trial will evaluate if the newly identified biomarkers of lung cancer in exhaled breath condensate are as a diagnostic tool comparable to the low-dose computer tomography (LDCT) implemented in lung cancer screening recently. Due to the possibility to collect breath condensate at any medical workplace and due to the relatively low financial cost of examination of the collected breath condensate could improve early diagnosis of lung cancer, differential diagnostics of lung nodules and thereby reduce both the unnecessary interventions and deaths from this type of cancer.Read full original descriptionShow less
Prospective Validation Study of Early Cancer Biomarkers in Breath Condensate of Individuals With High-Risk of Lung Cancer Undergoing Low-Dose Computer Tomography Based Screening.
The trial will evaluate if the newly identified biomarkers of lung cancer in exhaled breath condensate are as a diagnostic tool comparable to the low-dose computer tomography (LDCT) implemented in lung cancer screening recently. Due to the possibility to collect breath condensate at any medical workplace and due to the relatively low financial cost of examination of the collected breath condensate could improve early diagnosis of lung cancer, differential diagnostics of lung nodules and thereby reduce both the unnecessary interventions and deaths from this type of cancer.
Inclusion: Consent to participate in a clinical trial; A clients within an age of 55-74 years; Current smoker or ex-smoker who has smoked at least 20 pack-years, provided that:; priority will be given to clients who have smoked at least 30 pack-years; preference will be given to a former smoker who has not smoked for less than 15 years.
Exclusion: Previous diagnosis of lung cancer; Progressing malignant tumor on symptomatic treatment; Advanced dementia; Chronic obstructive pulmonary disease or other inflammatory disease in the phase of acute exacerbation.